Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Применение регорафениба при метастатическом колоректальном раке в реальной клинической практике
Применение регорафениба при метастатическом колоректальном раке в реальной клинической практике
Секачева М.И., Багмет Н.Н. Применение регорафениба при метастатическом колоректальном раке в реальной клинической практике. Современная Онкология. 2016; 18 (3): 43–47.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Проблема лечения метастатического колоректального рака заставляет продолжать поиски новых путей лечения этой сложной патологии. Регорафениб – новейший препарат для применения у пациентов, получивших все возможные варианты терапии. Эффективность и безопасность регорафениба подтверждена данными рандомизированных клинических исследований. В то время как в России препарат лишь недавно поступил на рынок, в мире уже накоплен обширный опыт его использования в реальной клинической практике, что позволяет выработать определенные подходы к отбору и ведению пациентов, добиваясь максимального результата. Обзору зарубежного и российского опыта посвящена данная статья.
Ключевые слова: регорафениб, метастатический колоректальный рак, реальная клиническая практика.
Key words: regorafenib, metastatic colorectal cancer, actual clinical practice.
Ключевые слова: регорафениб, метастатический колоректальный рак, реальная клиническая практика.
________________________________________________
Key words: regorafenib, metastatic colorectal cancer, actual clinical practice.
Полный текст
Список литературы
1. Van Cutsem E, Ciardiello F, Seitz JF et al. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. ESMO 17th World Congress on Gastrointestinal Cancer, 01–04 July 2015, Barcelona, Spain. Ann Oncol 2015; 26 (Suppl. 4): Abstract LBA-05.
2. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303–12.
3. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16: 619–29.
4. Ciardiello F, Falcone A, Cascinu S. et al. Sobrero Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study. The European Cancer Congress 2015, Vienna, Austria: Abstract 2143.
5. Van Cutsem E, Ciardiello F, Ychou M et al. Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial. J Clin Oncol, 2016 ASCO Annual Meeting (June 3–7, 2016). 2016; 34 (15. Suppl.): 3524.
6. Adenis A, de la Fouchardiere C, Paule B et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. BMC Cancer 2016; 16: 412.
7. Tabernero J, Lenz HJ, Siena S et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015; 16: 937–48.
8. Kopeckova K, Buchler T, Bortlicek Z et al. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. Target Oncol 2016.
9. Zanwar S, Ostwal V, Gupta S et al. Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. Ann Transl Med 2016; 4 (4): 74.
2. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303–12.
3. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16: 619–29.
4. Ciardiello F, Falcone A, Cascinu S. et al. Sobrero Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study. The European Cancer Congress 2015, Vienna, Austria: Abstract 2143.
5. Van Cutsem E, Ciardiello F, Ychou M et al. Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial. J Clin Oncol, 2016 ASCO Annual Meeting (June 3–7, 2016). 2016; 34 (15. Suppl.): 3524.
6. Adenis A, de la Fouchardiere C, Paule B et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. BMC Cancer 2016; 16: 412.
7. Tabernero J, Lenz HJ, Siena S et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015; 16: 937–48.
8. Kopeckova K, Buchler T, Bortlicek Z et al. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. Target Oncol 2016.
9. Zanwar S, Ostwal V, Gupta S et al. Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. Ann Transl Med 2016; 4 (4): 74.
2. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303–12.
3. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16: 619–29.
4. Ciardiello F, Falcone A, Cascinu S. et al. Sobrero Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study. The European Cancer Congress 2015, Vienna, Austria: Abstract 2143.
5. Van Cutsem E, Ciardiello F, Ychou M et al. Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial. J Clin Oncol, 2016 ASCO Annual Meeting (June 3–7, 2016). 2016; 34 (15. Suppl.): 3524.
6. Adenis A, de la Fouchardiere C, Paule B et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. BMC Cancer 2016; 16: 412.
7. Tabernero J, Lenz HJ, Siena S et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015; 16: 937–48.
8. Kopeckova K, Buchler T, Bortlicek Z et al. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. Target Oncol 2016.
9. Zanwar S, Ostwal V, Gupta S et al. Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. Ann Transl Med 2016; 4 (4): 74.
________________________________________________
2. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303–12.
3. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16: 619–29.
4. Ciardiello F, Falcone A, Cascinu S. et al. Sobrero Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study. The European Cancer Congress 2015, Vienna, Austria: Abstract 2143.
5. Van Cutsem E, Ciardiello F, Ychou M et al. Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial. J Clin Oncol, 2016 ASCO Annual Meeting (June 3–7, 2016). 2016; 34 (15. Suppl.): 3524.
6. Adenis A, de la Fouchardiere C, Paule B et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. BMC Cancer 2016; 16: 412.
7. Tabernero J, Lenz HJ, Siena S et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015; 16: 937–48.
8. Kopeckova K, Buchler T, Bortlicek Z et al. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. Target Oncol 2016.
9. Zanwar S, Ostwal V, Gupta S et al. Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. Ann Transl Med 2016; 4 (4): 74.
Авторы
М.И.Секачева*, Н.Н.Багмет
ФГБНУ Российский научный центр хирургии им. акад. Б.В.Петровского. 119991, Россия, Москва, Абрикосовский пер., д. 2
*sekach_rab@mail.ru
B.V.Petrovskiy Russian Scientific Center of Surgery. 119991, Russian Federation, Moscow, Abrikosovskii per., d. 2
*sekach_rab@mail.ru
ФГБНУ Российский научный центр хирургии им. акад. Б.В.Петровского. 119991, Россия, Москва, Абрикосовский пер., д. 2
*sekach_rab@mail.ru
________________________________________________
B.V.Petrovskiy Russian Scientific Center of Surgery. 119991, Russian Federation, Moscow, Abrikosovskii per., d. 2
*sekach_rab@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.